Loading
PDBj
MenuPDBj@FacebookPDBj@X(formerly Twitter)PDBj@BlueSkyPDBj@YouTubewwPDB FoundationwwPDBDonate
RCSB PDBPDBeBMRBAdv. SearchSearch help

1QLP

2.0 ANGSTROM STRUCTURE OF INTACT ALPHA-1-ANTITRYPSIN: A CANONICAL TEMPLATE FOR ACTIVE SERPINS

Replaces:  2PSI
Summary for 1QLP
Entry DOI10.2210/pdb1qlp/pdb
Related1ATU 1KCT 1PSI 2PSI 7API 8API 9API
DescriptorALPHA-1-ANTITRYPSIN (2 entities in total)
Functional Keywordsserine protease inhibitor, serpin, glycoprotein, polymorphism, emphysema, disease mutation, acute phase
Biological sourceHOMO SAPIENS (HUMAN)
Total number of polymer chains1
Total formula weight44380.44
Authors
Elliott, P.R.,Pei, X.Y.,Dafforn, T.,Read, R.J.,Carrell, R.W.,Lomas, D.A. (deposition date: 1999-09-10, release date: 1999-09-27, Last modification date: 2023-12-13)
Primary citationElliott, P.R.,Pei, X.Y.,Dafforn, T.R.,Lomas, D.A.
Topography of a 2.0 A structure of alpha1-antitrypsin reveals targets for rational drug design to prevent conformational disease.
Protein Sci., 9:1274-1281, 2000
Cited by
PubMed Abstract: Members of the serpin family of serine proteinase inhibitors play important roles in the inflammatory, coagulation, fibrinolytic, and complement cascades. An inherent part of their function is the ability to undergo a structural rearrangement, the stressed (S) to relaxed (R) transition, in which an extra strand is inserted into the central A beta-sheet. In order for this transition to take place, the A sheet has to be unusually flexible. Malfunctions in this flexibility can lead to aberrant protein linkage, serpin inactivation, and diseases as diverse as cirrhosis, thrombosis, angioedema, emphysema, and dementia. The development of agents that control this conformational rearrangement requires a high resolution structure of an active serpin. We present here the topology of the archetypal serpin alpha1-antitrypsin to 2 A resolution. This structure allows us to define five cavities that are potential targets for rational drug design to develop agents that will prevent conformational transitions and ameliorate the associated disease.
PubMed: 10933492
DOI: 10.1110/ps.9.7.1274
PDB entries with the same primary citation
Experimental method
X-RAY DIFFRACTION (2 Å)
Structure validation

237735

數據於2025-06-18公開中

PDB statisticsPDBj update infoContact PDBjnumon